AIM: To evaluate the association between p53 codon 72 polymorphism and liver cancer risk by means of meta-analysis. METHODS: Two investigators independently searched the Medline, Embase and Chinese Biomedicine databases. Summary odds ratios and 95% CI for p53 codon 72 polymorphism and liver cancer were calculated in fixed-effects model (Mantel-Haenszel method) and random-effects model (DerSimonian and Laird method) when appropriate. RESULTS: This meta-analysis included 1115 liver cancer cases and 1778 controls. The combined results based on all studies showed that there was a statistically significant link between Pro/Pro genotype and liver cancer, but not between Arg/Arg or Pro/Arg genotype and liver cancer. When stratifying for race, similar results were obtained, i.e. patients with liver cancer had a significantly higher frequency of Pro/Pro genotype than non-cancer patients among Asians. After stratifying the various studies by control source, gender, family history of liver cancer and chronic hepatitis virus infection, we found that (1) patients among hospital-based studies had a significantly higher frequency of Pro/Pro and a significantly lower frequency of Arg/Arg genotype than individuals without cancer; (2) female patients with liver cancer had a significantly lower frequency of Arg/Arg and a higher frequency of Pro/Arg+Pro/Pro genotypes than female individuals without cancer; (3) subgroup analyses for family history of liver cancer did not reveal any significant association between p53 codon 72 polymorphism and liver cancer development; and (4) patients with negative hepatitis virus infection had a significantly higher frequency of Pro/Pro and a significantly lower frequency of Arg/Arg genotype than individuals without cancer. CONCLUSION: This meta-analysis suggests that the p53 codon 72 polymorphism may be associated with liver cancer among Asians.
AIM: To evaluate the association between p53 codon 72 polymorphism and liver cancer risk by means of meta-analysis. METHODS: Two investigators independently searched the Medline, Embase and Chinese Biomedicine databases. Summary odds ratios and 95% CI for p53 codon 72 polymorphism and liver cancer were calculated in fixed-effects model (Mantel-Haenszel method) and random-effects model (DerSimonian and Laird method) when appropriate. RESULTS: This meta-analysis included 1115 liver cancer cases and 1778 controls. The combined results based on all studies showed that there was a statistically significant link between Pro/Pro genotype and liver cancer, but not between Arg/Arg or Pro/Arg genotype and liver cancer. When stratifying for race, similar results were obtained, i.e. patients with liver cancer had a significantly higher frequency of Pro/Pro genotype than non-cancerpatients among Asians. After stratifying the various studies by control source, gender, family history of liver cancer and chronic hepatitis virus infection, we found that (1) patients among hospital-based studies had a significantly higher frequency of Pro/Pro and a significantly lower frequency of Arg/Arg genotype than individuals without cancer; (2) female patients with liver cancer had a significantly lower frequency of Arg/Arg and a higher frequency of Pro/Arg+Pro/Pro genotypes than female individuals without cancer; (3) subgroup analyses for family history of liver cancer did not reveal any significant association between p53 codon 72 polymorphism and liver cancer development; and (4) patients with negative hepatitis virus infection had a significantly higher frequency of Pro/Pro and a significantly lower frequency of Arg/Arg genotype than individuals without cancer. CONCLUSION: This meta-analysis suggests that the p53 codon 72 polymorphism may be associated with liver cancer among Asians.
Authors: H Kuper; A Tzonou; E Kaklamani; C C Hsieh; P Lagiou; H O Adami; D Trichopoulos; S O Stuver Journal: Int J Cancer Date: 2000-02-15 Impact factor: 7.396
Authors: R K Ross; J M Yuan; M C Yu; G N Wogan; G S Qian; J T Tu; J D Groopman; Y T Gao; B E Henderson Journal: Lancet Date: 1992-04-18 Impact factor: 79.321
Authors: G S Qian; R K Ross; M C Yu; J M Yuan; Y T Gao; B E Henderson; G N Wogan; J D Groopman Journal: Cancer Epidemiol Biomarkers Prev Date: 1994 Jan-Feb Impact factor: 4.254
Authors: Valeria Di Vuolo; Luigi Buonaguro; Francesco Izzo; Simona Losito; Gerardo Botti; Franco M Buonaguro; Maria Lina Tornesello Journal: Infect Agent Cancer Date: 2011-08-15 Impact factor: 2.965
Authors: Y He; X Du; J Y Weng; C X Deng; S X Geng; Z S Lu; M M Li; P J Liao; C W Luo; S J Wu; L Y Zhong Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2017-02-14